Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Unspecified Adult Solid Tumor, Protocol Specific 4Advanced Solid Tumors 4Solid Tumors 2Solid Tumor 2Mesothelioma, Malignant 2Mesothelioma 2Unresectable Locally Advanced or Metastatic Solid Tumors 1Triple Negative Breast Neoplasms 1Solid Malignancy 1Relapsed Pediatric Solid Tumor 1Cholangiocarcinoma of the Gallbladder 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Advanced Malignant Solid Neoplasm 1Advanced Cancers 1Advanced Cancer 1

Interventions

pazopanib 2Ifosfamide 2Etoposide 2Carboplatin 2vandetanib 1ruxolitinib 1fludarabine 1Vemurafenib 1Trastuzumab 1Sorafenib 1Imatinib Mesylate 1Everolimus 1Erlotinib Hydrochloride 1Dasatinib 1Cytarabine 1Crizotinib 1Axitinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Relapsed Pediatric Solid Tumor × Everolimus × Other solid neoplasm × Clear all
NCT02638428 2020-03-19

Genomics-Based Target Therapy for Children With Relapsed or Refractory Malignancy

Samsung Medical Center

Phase 2 Unknown
90 enrolled
Other solid neoplasm

Relapsed Pediatric Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡